Page 23«..1020..22232425..30..»

Category : Nanomedicine

UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News

When Dr. Pere Santamaria arrived in Calgary in 1992 to join the Cumming School of Medicine, he never could have imagined he would make a groundbreaking discovery that would lead to a spinoff company. When I arrived, I found out that the grant money I was expecting hadnt come through, says Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases and member of the Snyder Institute for Chronic Diseases. So I had an empty lab with no research assistants and no salary. I had to beg my supervisor to give me $10,000 to start my research.

Despite the rocky start, Santamaria has achieved something many scientists dream of making a discovery that has practical applications for health care. Santamarias discovery revolves around the use of nanoparticles coated in proteins to treat autoimmune and inflammatory disorders.

They can be modified for different diseases, such as Type 1 diabetes, multiple sclerosis and rheumatoid arthritis without compromising the entire immune system, Santamaria explains. Instead, they basically work to reset the immune system.

Nanomedicines unique mechanism has the potential to disrupt the pharmaceutical industry entirely. Developing a new class of drugs is rare. With the assistance of Innovate Calgary, Santamaria started a company, Parvus Therapeutics Inc., to represent the technology and explore ways of bringing it to market. Announced in April 2017, Parvus entered into an exclusive deal with the Swiss pharma giant Novartis, hopefully leading to the development and commercialization of Parvuss nanomedicine to treat Type 1 diabetes.

Its a good partnership, Santamaria says. Bringing a drug to market requires science as well as money.

Supporting commercialization should be a top priority for all research, he continues. Our biggest responsibility is to the patients and making sure they have access to the medicine they need. With that in mind, Santamaria shares his insight for other researchers who may be interested in bringing their discoveries from the lab bench to the market.

If youre interested in investigating spin-out opportunities, get in touch with Innovate Calgary, which offers mentors, coaching, business skill development programs, intellectual property services and other back-office support.

Throughout the years, Santamarias work has been funded by numerous organizations, including Diabetes Canada, the Juvenile Diabetes Research Foundation, the Canadian Institutes of Health Research (CIHR) and the Diabetes Association, Foothills.He is a member of the Snyder Institute and associate member of the Hotchkiss Brain Institute.Santamaria named his company Parvus from the Greek word meaning small.

Continue reading here:
UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes - UCalgary News

Recommendation and review posted by Alexandra Lee Anderson

‘Blazing the trail’: University of Calgary research could lead to cures for autoimmune diseases –

Researchers at the University of Calgary say their work in the field of "nanomedicine"could lead to cures for Type 1 diabetes, multiple sclerosis and many more diseases.

Dr. Pere Santamaria said the process involves "nanoparticles" thousands of times smaller than a typicalhuman cell that could be used to stop the body from attacking itself.

That, he said, could potentially lead to cures for autoimmunedisorders.

"There are no drugs that can do that today,"said Santamaria, aprofessor ofimmunology at the University of Calgary.

"Other drugs that are being used to treat chronic inflammatory disorders impair the ability of the immune system to do its job, so there are secondary effects and longterm complications our drugs don't do that."

Pharmaceutical company Novartis has partnered with Santamaria's own company, Parvus Therapeutics, to work on developing the nanomedicines and take the drugs to market.

Now with support and funding, Santamariasaid the new drug"has the potential to revolutionizemedicine" if the drugs pass clinical testing.

Santamariasaid autoimmune disordersarecaused by white blood cells attacking the tissues in a person'sown body.

Pharmaceutical company Novartis has partnered with Dr. Santamaria's Parvus Therapeutics to work on developing nanomedicines to cure autoimmune disorders and take the drugs to market. (CBC)

Type 1 diabetesis treatable with insulin, but there is no cure. It's the same for many other diseases.

"Our drugs aim to resolve the inflammation of the tissue, the attack of the tissue, and resolve that process altogether," Santamaria said.

He said the nanoparticles could halt disorders without impairing the rest of the immune system.

"So we can reset the immune system to its steady state that means the healthy state without impairing the ability of our immune system to protect us against infections and cancer,"Santamariasaid.

Santamaria said the nanoparticleswere discovered during an experiment years ago, and the initialtestresults"made nosensewhatsoever." Since that day, the nanomedicines havebeen in development and he credits the progress to curiosity.

"We almost shoved them under the rug," Santamaria said."We didn't do that. Fortunately, we were pursued wth curiosity of researching."

Santamaria said the process of taking a discovery from the research laboratory to the marketplace is enormously complex and the drug has yet to go through preclinical trials.

Because nanomedicine is such a new field of research, there is no firm timeline on when the medicinescould be available if they pass human trials.

"Our nanomedicineis a new class of drug ... so we're basically blazing the trail," Santamaria said.

"We hope that we can carry that torch and be an example for all the investigators that might follow suit, that may run into discoveries such as the ones that we've made and hopefully they can follow in our footsteps."

View original post here:
'Blazing the trail': University of Calgary research could lead to cures for autoimmune diseases -

Recommendation and review posted by Alexandra Lee Anderson

International Conference and Exhibition on Nanomedicine and Nanotechnology – Technology Networks

Short Name: Nanomed Meeting 2017

Theme: Challenges and Innovations in next generation medicine


Registration Link:

Nanomed Meeting 2017 Organizing Committee invites you to attend the largest assemblage of Nanomedicine and Nanotechnology researchers from around the globe during November 23-24, 2017 at Dubai, UAE.

Nanomed Meeting 2017 is a global annual event. This International Conference and Exhibition on Nanomedicine and Nanotechnology brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of Nanomed Meeting 2017 through a decade at Asia finds much requirement for discussion also focusing the latest developments in the field of Nanomedicine and Nanotechnology.

Why attend?

Join your peers around the world focused on learning about Nanomedicine and Nanotechnology related advances, which is your single best opportunity to reach the largest assemblage of participants from the Nanomedicine and Nanotechnology community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Nanomedicine and Nanotechnology are hallmarks of this conference.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Read more:
International Conference and Exhibition on Nanomedicine and Nanotechnology - Technology Networks

Recommendation and review posted by Alexandra Lee Anderson

Cancer survivor becomes a cancer fighter at a Philly start-up –

What Debra Travers really wanted to be was a marine biologist, until I found out Jacques Cousteau wasnt hiring.

How she wound up as chief executive of PolyAurum LLC, a Philadelphia start-up developing biodegradable gold nanoparticles for treating cancerous tumors, involved a professional journey of more than 30 years in pharmaceutical and diagnostics industries, and a personal battle with the disease shes now in business to defeat.

After determining that studying sea creatures was not a viable career choice, Travers a military kid from all over switched her major at Cedar Crest College in Allentown to medical technology. She graduated in 1979, then worked for three years in a hospital laboratory until she concluded she didnt like shift work and could do more.

What followed was an impressive career progression: Travers started as a chemistry technician at DuPont Biomedical Products Division, advancing to executive positions in marketing and product development at Centocor, GlaxoSmithKline, Endo Pharmaceuticals, and IMS Health.

Much of that work involved bringing new products through the long development and regulation-heavy process from concept to launch, with experience in therapeutic areas including oncology, urology, pain medicine, cardiology, and rheumatology. In an industry of specialty silos, Travers developed a uniquely blended expertise in marketing and R&D.

It was on March 23, 2006, that her health-care vocation turned personal: Travers, then a 50-year-old mother of two, was diagnosed with breast cancer.

An oncologist recommended a double mastectomy, removal of both ovaries, and chemotherapy. The tearful pleadings of her daughter, Kelly, then 18 I need you here when I graduate college, when I get married, when I have kids persuaded Travers to follow that recommendation.

She returned to work at Endo for seven more years, as a director in project management, before being laid off in June 2013, one month before her daughters wedding. The break gave Travers time to concentrate on the big event and to start to think what Id like to do when I grow up.

That process would lead her in late 2015 to PolyAurum, a start-up spun out of the University of Pennsylvania.

I became a CEO and a grandmother in the same year, said Travers, now 61, chuckling during a recent interview at the Pennovation Center incubator in West Philadelphia. From there, her home in Delaware, and the sites of pitch opportunities with investors, she is working to raise $1.3 million in seed funding by early in the fourth quarter, to help get PolyAurum closer to clinical trials on humans.

So far, research and testing funded through $4 million in grants to the university has been limited to mice with tumors. It has shown that gold nanocrystals greatly enhance the effectiveness of radiation on tumors without increasing harm to healthy surrounding tissue, said Jay Dorsey, an associate professor and radiation oncologist at Penn and one of four university faculty who developed the technology.

The effectiveness of metals in improving a tumors ability to absorb radiation has long been known, Dorsey said. But one of the stumbling blocks to incorporating gold nanoparticles in such therapeutics is that the metal is not eliminated from the body well, posing serious problems to vital organs such as the liver and spleen.

Penns David Cormode, a professor of radiology, and Andrew Tsourkas, a professor of bioengineering, have worked to make gold more biocompatible, resulting in PolyAurums current technology, Dorsey said. The gold nanocrystals are contained in a biodegradable polymer that allows enough metal to collect in a tumor. The polymer then breaks down, releasing the gold for excretion from the body so that it does not build up in key organs.

The companys name is a combination of those two essential ingredients: Poly, derived from polymer, and Aurum, the Latin word for gold.

Explaining all that, and the potential that PolyAurums founders see for extending and saving lives, is the message Travers now is in charge of disseminating the part of the critical path to commercialization that is not the strength of most researchers toiling in laboratories.

She knows what the founders dont know it just makes a perfect match, said Michael Dishowitz, portfolio manager at PCI Ventures, an arm of Penn that helps university start-ups find investors, recruit management, and get to market.

Since its formation about eight years ago, PCI has helped more than 150 companies secure more than $100 million in funding, said Dishowitz, who has a doctoratein bioengineering from Penn and spent several years studying the impact of cell-signaling pathways on orthopedic injury.

While calling PolyAurums technology cool and very transformative for treatment, Dishowitz also delivered a dose of reality about the rigors ahead, as health-care start-ups must navigate a course with no guarantees their products will lead to actual clinical implementation.

PolyAurum is one of 13 companies that entered Philadelphia Media Networks second annual Stellar StartUps competition in the health-care/life sciences category. A total of nine categories drew 88 applicants. The winners will be announced Sept. 12 at an event at the Franklin Institutes Fels Planetarium. (Details at

A lot has to go right, all the planets and stars have to align for this to hit the market, Dishowitz said of PolyAurums commercial prospects.

Which is why the team behind any start-up is so essential to investors, he said, calling Travers interest in joining a company that has yet been unable to pay her (she has equity in PolyAurum) incredibly lucky.

Margo Reed

At the Nanomedicine and Molecular Imaging Lab at Penn Medicine are (front row, from left) Jay Dorsey, a radiation oncologist and a founder of PolyAurum; Debra Travers, CEO; and Andrew Tsourkas, another founder of PolyAurum; and (back row, from left) Michael Dishowitz, portfolio manager, PCI Ventures at Penn; and David Cormode, lab director and PolyAurum founder. (MARGO REED / Staff Photographer)

The only thing Travers corporate-heavy background lacked, he said, was raising money for a start-up. It doesnt worry him, Dishowitz said, citing Travers perseverance, no-quit attitude.

When youre out there raising money, youre going to hear no about 100, 150 times before you hear yes, Dishowitz said.

When it comes to pitching for PolyAurum, Travers has extra incentive.

I am working on a cancer therapeutic, which is very important to the 11-year cancer survivor in me, she said.

As for handling nos, shes had plenty of professional experience with that.

After spending 30-plus years in the drug and diagnostic industries, where it is hard to find women CEOs or board members, Travers said, Ive learned to ignore the negative voices.

When: 5:30-8:30 p.m. Tuesday, Sept. 12.

Where: Fels Planetarium, Franklin Institute, 222 N. 20th St., Philadelphia 19103

For more information:

Published: July 28, 2017 3:01 AM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day.We're thankful for your support in every way.

See more here:
Cancer survivor becomes a cancer fighter at a Philly start-up -

Recommendation and review posted by Alexandra Lee Anderson

Application of Nanomaterials in the Field of Medicine – Medical News Bulletin

There has been a growing interest in the different applications of nanomaterials in the field of medicine. An article published in Nanomedicine: Nanotechnology, Biology, and Medicine showed the ways in which Laponite, a synthetic clay made of nanomaterials, can be of use in clinical practice.

Current advances in technology have provided many opportunities to develop new devices that improve the practice of medicine. There has been a growing interest in the different applications of nanomaterials in the field of medicine.

An article published in Nanomedicine: Nanotechnology, Biology, and Medicine reviewed Laponite, a non-toxic synthetic clay composed of nanomaterials which has different uses in the field of medicine. Laponite can be used in drug delivery systems, as the synthetic clay protects substances from degradation in physiologic environments. Different experiments show that Laponite is effective not only in protecting drugs from degradation, but also in transporting and releasing drugs into the body. The degradation of Laponite in the physiologic environment also releases products which have biological roles, especially in bone formation.

Laponite has been shown to induce osteogenic differentiation of cells in the absence of other factors which are known to promote differentiation and cell growth. The application of nanomaterials in bioimaging has also been studied. In one experiment, Laponite was incorporated with gadolinum, a dye used in magnetic resonance imaging (MRI), resulting in brighter images and prolonged contrast enhancement for 1 hour post-injection. Laponite has also proven to be of use in the field of regenerative medicine and tissue engineering. This synthetic clay can elicit specific biologic responses, act as a carrier for biochemical factors, and improve the mechanical properties of scaffolds used for tissue growth.

In summary, nanomaterials and synthetic clays such as Laponite have many applications in the field of medicine. Although current published literature state no toxic effects on the human body, further studies are needed to assess safety before it can be applied to clinical practice.

Written By:Karla Sevilla

Add to Flipboard Magazine.

See the rest here:
Application of Nanomaterials in the Field of Medicine - Medical News Bulletin

Recommendation and review posted by Alexandra Lee Anderson

Nanobiotix Revenues for the 2nd Quarter of 2017 – Markets Insider

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited revenues for the second quarter of 2017.

Income statement

Activity and results

Total revenues for the second quarter amounts to 58,645, which is fully in line with the Companys expectations.

For this period, most of the revenues are generated from services that Nanobiotix crossed-charged to its partners as per its operational activities.

In May, Nanobiotix announced a first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold tumors into "hot tumors. The new clinical data and previous pre-clinical data indicate that NBTXR3 could play a key role in oncology and could become a backbone in immuno-oncology.

Nanobiotix presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago in June. The excellent safety profile demonstrated in this elderly and frail population so far indicates that NBTXR3 would represent a valuable option to preserve and improve patients Quality of Life compared to other treatments. This safety profile also opens up opportunities for combinations with different types of treatments. These encouraging results point towards a positive improvement of loco-regional Control, impacting Overall Survival of the patients.

Nanobiotix is filing a protocol amendment of this study to include 44 additional patients in an expansion to demonstrate the efficacy of NBTXR3. Nanobiotix is opening 12-15 additional sites in Europe to expand the development of this indication, and plans to expand this study in the US.

Finally, in mid-June, Nanobiotix presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC) in Bethesda, Maryland, USA. Taken together, these non-clinical and preliminary clinical results confirm that NBTXR3 plus radiotherapy could efficiently prime an adaptive antitumor immune response, turning "cold tumors in "hot tumors. Additionally, these results suggest that the physically-induced response and subsequent immune activation triggered by the NBTXR3 treatment could be generic. NBTXR3 with radiotherapy could transform tumors into an effective in situ vaccine, opening up very promising perspectives in the treatment of local cancer and metastases.


Next financial press release: revenue for the first half of 2017 to be released on August 31, 2017.


Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotixs Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.


This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorit des Marchs Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

View source version on

Nanobiotix Revenues for the 2nd Quarter of 2017 - Markets Insider

Recommendation and review posted by Alexandra Lee Anderson

Precision NanoSystems to Host Nanomedicines Symposium – Technology Networks

Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15th of July in Boston, MA. Following the success of last years inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Societys Annual Meeting and Exposition from the 16th to 18th of July.

The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address To target or not to target: lessons from RNAi-based targeted lipid nanoparticles being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.

The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich as well as providing networking opportunities throughout the day.

The rest is here:
Precision NanoSystems to Host Nanomedicines Symposium - Technology Networks

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine opens door to precision medicine for brain tumors – Phys.Org

Killer T cells surround a cancer cell. Credit: NIH

Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor initiating cells (BTICs).

"BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy," explained the study's first author, Dr. Dou Yu, research assistant professor of neurological surgery at Northwestern University Feinberg School of Medicine.

The findings were published in the journal Proceedings of the National Academy of Sciences.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA)short sequences of RNA molecules that reduce the expression of specific cancer promoting proteinsdirectly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

"This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind," said Yu, who collaborated on the research with principal investigator Dr. Maciej Lesniak, Michael J. Marchese Professor of Neurosurgery and chair of neurological surgery.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patient's tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissuesbut not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

"This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling," Yu said. "Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits."

The strategy could also apply to other medical conditions related to the central nervous systemnot just brain tumors.

"Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform," Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

"Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer," Lesniak summed up.

Explore further: Cold virus, stem cells tested to destroy deadly brain cancer

More information: Dou Yu et al, Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1701911114

The rest is here:
Nanomedicine opens door to precision medicine for brain tumors - Phys.Org

Recommendation and review posted by Alexandra Lee Anderson

Koch Institute’s Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer – AZoNano

Written by AZoNanoJul 10 2017

The Koch Institute for Integrative Cancer Research at MIT will soon be reaching the first anniversary of the launch of the Marble Center for Cancer Nanomedicine, founded through a generous gift from Kathy and Curt Marble 63.

The Marble Center for Cancer Nanomedicines faculty is made up of Koch Institute members who are committed to fighting cancer with nanomedicine through research, education, and collaboration. Top row (l-r) Sangeeta Bhatia, director; Daniel Anderson; and Angela Belcher. Bottom row: Paula Hammond; Darrell Irvine; and Robert Langer. (Photo: Koch Institute Marble Center for Cancer Nanomedicine)

Bringing together leading Koch Institute faculty members and their teams, the Marble Center for Cancer Nanomedicine focuses on huge challenges in cancer detection, treatment and monitoring that can profit from the latest physics and biology of the nanoscale.

These challenges include spotting cancer earlier than present techniques allow, harnessing the immune system to combat cancer even as it progresses, using therapeutic insights from cancer biology to design therapies for formerly undruggable targets, integrating current drugs for synergistic action, and developing tools for more accurate diagnosis and improved surgical intervention.

Koch Institute member Sangeeta N. Bhatia, the John J. and Dorothy Wilson, Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, serves as the Inaugural Director of the center.

A major goal for research at the Marble Center is to leverage the collaborative culture at the Koch Institute to use nanotechnology to improve cancer diagnosis and care in patients around the world.

Sangeeta N. Bhatia, Koch Institute Member

Transforming nanomedicine

The Marble Center joins MITs larger efforts at the forefront of discovery and advancement to solve the critical global challenge that is cancer. The concept of convergence the combination of the life and physical sciences with engineering is a trademark of MIT, the founding principle of the Koch Institute, and at the heart of the Marble Centers mission.

The center galvanizes the MIT cancer research community in efforts to use nanomedicine as a translational platform for cancer care. Its transformative by applying these emerging technologies to push the boundaries of cancer detection, treatment, and monitoring and translational by promoting their development and application in the clinic.

Tyler Jacks, Director of the Koch Institute and a David H. Koch Professor of Biology

The centers faculty six renowned MIT Professors and Koch Institute Members are committed to combating cancer with nanomedicine through research, education and partnership. They are, Sangeeta Bhatia (director), the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science; Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology in the Department of Chemical Engineering and the Institute for Medical Engineering and Science; Angela M. Belcher, the James Mason Crafts Professor in the departments of Biological Engineering and Materials Science and Engineering; Paula T. Hammond, the David H. Koch Professor of Engineering and head of the Department of Chemical Engineering; Darrell J. Irvine, Professor in the departments of Biological Engineering and Materials Science and Engineering; and Robert S. Langer, the David H. Koch Institute Professor.

Extending their partnership within the walls of the Institute, members of the Marble Center profit greatly from the support of the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institutes Robert A. Swanson (1969) Biotechnology Center. The Peterson Facilitys array of technological resources and know-how is unparalleled in the United States, and gives members of the center and of the Koch Institute, a distinctive advantage in the development and application of materials and technologies at the nanoscale.

Looking ahead

The Marble Center made the most of its first year, and has provided backing for advanced research projects including theranostic nanoparticles that can both detect and treat cancers, real-time imaging of interactions between cancer and immune cells to properly understand reaction to cancer immunotherapies, and delivery technologies for a number of powerful RNA-based therapeutics capable of engaging specific cancer targets with precision.

As part of its efforts to help adopt a multifaceted science and engineering research force, the center has offered fellowship support for trainees as well as valuable opportunities for scientific exchange, mentorship and professional development.

Promoting wider engagement, the Marble Center serves as a bridge to a broad network of nanomedicine resources, linking its members to MIT.nano, other Nanotechnology Researchers, and Clinical Partners across Boston and beyond. The center has also set up a scientific advisory board, whose members come from leading clinical and academic centers around the country, and will assist in shaping the centers future programs and continued development.

As the Marble Center enters another year of partnerships and innovation, there is a new landmark in sight for 2018. Nanomedicine has been chosen as the main theme for the Koch Institutes 17th Annual Cancer Research Symposium. The event is scheduled for June 15th, 2018, and will bring together national domain experts, providing a perfect forum for Marble Center members to share the discoveries and progresses made during its sophomore year.

Having next years KI Annual Symposium dedicated to nanomedicine will be a wonderful way to further expose the cancer research community to the power of doing science at the nanoscale. The interdisciplinary approach has the power to accelerate new ideas at this exciting interface of nanotechnology and medicine.

Sangeeta N. Bhatia, Koch Institute Member

Read the original here:
Koch Institute's Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer - AZoNano

Recommendation and review posted by Alexandra Lee Anderson

Global Nanomedicine Market 2017 GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc. – Ask Reporter 24

The worldwide Nanomedicine Market report is an in-depth research on the current situation of the Nanomedicine industry. The research study of Global Nanomedicine Market 2017 offers a strategic assessment of Nanomedicine market. The industry report focuses on the growth opportunities, which will help the Nanomedicine industry to expand operations in the existing markets globally.

Firstly, Nanomedicine Market report introduces a basic overview of the Nanomedicine industry, which includes Nanomedicine definitions, applications, classifications and Nanomedicine industry chain structure. Worldwide Nanomedicine market analysis is provided for the international market including Nanomedicine industry competitive analysis, Nanomedicine market development history and major sectors development status on Nanomedicine industry scenario.

Get Sample Report Here:

Global Nanomedicine Market 2017: Competitive Landscape and Key Vendors

1 GE Healthcare 2 Johnson & Johnson 3 Mallinckrodt plc 4 Merck & Co. Inc. 5 Nanosphere Inc. 6 Pfizer Inc. 7 Sigma-Tau Pharmaceuticals Inc. 8 Smith & Nephew PLC 9 Stryker Corp 10 Teva Pharmaceutical Industries Ltd. 11 UCB (Union chimique belge)

Nanomedicine Market 2017: Type Segment Analysis

Regenerative Medicine In-vitro & In-vivo Diagnostics Vaccines Drug Delivery

Nanomedicine Market 2017: Applications Segment Analysis

Clinical Cardiology Urology Genetics Orthopedics Ophthalmology

The Nanomedicine market covers the geological regions including US, EU, China, and Japan. Other regions can also be added efficiently as per customers need. The report also displays the market size for each category during the forecasting period from 2017 to 2022.

Further, the report guides the client according to the various aspects of Nanomedicine industry like supply chain analysis, Nanomedicine industry rules, and policies, along with product cost, product images, the cost structure, import/export information and utilisation figures. The detailed competitive plan of Nanomedicine industry report will help the clients to systematically specify better business strategies for a desired business payoff.

To Purchase Complete Report Click Here:

At the end, report Global Nanomedicine Market 2017 focuses the feasibility of new investment projects is assessed, and overall research conclusions are offered on Nanomedicine market scenario.

Global Nanomedicine Market 2017 GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc. - Ask Reporter 24

Recommendation and review posted by Alexandra Lee Anderson

Page 23«..1020..22232425..30..»